Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:6099476rdf:typepubmed:Citationlld:pubmed
pubmed-article:6099476lifeskim:mentionsumls-concept:C0242402lld:lifeskim
pubmed-article:6099476lifeskim:mentionsumls-concept:C1882864lld:lifeskim
pubmed-article:6099476lifeskim:mentionsumls-concept:C0441889lld:lifeskim
pubmed-article:6099476lifeskim:mentionsumls-concept:C0005456lld:lifeskim
pubmed-article:6099476pubmed:issue1-3lld:pubmed
pubmed-article:6099476pubmed:dateCreated1985-4-26lld:pubmed
pubmed-article:6099476pubmed:abstractTextOpioid receptor binding sites were analyzed in various segments of rat spinal cord. Mu and delta types were labelled with [3H]-DHM or [3H]-DAGO and [3H]-DADLE or [3H]-DSLET respectively. Kappa 1 (kappa) and kappa 2 (benzomorphan) binding sites were individually detected by the overall labeling of opioid binding sites with [3H]-etorphine followed by the elimination of binding to particular sites by the use of appropriate selective unlabelled ligands. Whereas lumbo sacral region contained mainly the kappa 2 site, thoracic membranes had a proportion of approximately 20% mu, 20% kappa 1 and 60% kappa 2 and cervical region contained much less kappa 2 sites (25% mu, 20% delta, 28% kappa 1 and 32% kappa 2).lld:pubmed
pubmed-article:6099476pubmed:languageenglld:pubmed
pubmed-article:6099476pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6099476pubmed:citationSubsetIMlld:pubmed
pubmed-article:6099476pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6099476pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6099476pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6099476pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6099476pubmed:statusMEDLINElld:pubmed
pubmed-article:6099476pubmed:monthDeclld:pubmed
pubmed-article:6099476pubmed:issn0143-4179lld:pubmed
pubmed-article:6099476pubmed:authorpubmed-author:CrosJJlld:pubmed
pubmed-article:6099476pubmed:authorpubmed-author:GouardèresCClld:pubmed
pubmed-article:6099476pubmed:issnTypePrintlld:pubmed
pubmed-article:6099476pubmed:volume5lld:pubmed
pubmed-article:6099476pubmed:ownerNLMlld:pubmed
pubmed-article:6099476pubmed:authorsCompleteYlld:pubmed
pubmed-article:6099476pubmed:pagination113-6lld:pubmed
pubmed-article:6099476pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:6099476pubmed:meshHeadingpubmed-meshheading:6099476-...lld:pubmed
pubmed-article:6099476pubmed:meshHeadingpubmed-meshheading:6099476-...lld:pubmed
pubmed-article:6099476pubmed:meshHeadingpubmed-meshheading:6099476-...lld:pubmed
pubmed-article:6099476pubmed:meshHeadingpubmed-meshheading:6099476-...lld:pubmed
pubmed-article:6099476pubmed:meshHeadingpubmed-meshheading:6099476-...lld:pubmed
pubmed-article:6099476pubmed:meshHeadingpubmed-meshheading:6099476-...lld:pubmed
pubmed-article:6099476pubmed:meshHeadingpubmed-meshheading:6099476-...lld:pubmed
pubmed-article:6099476pubmed:meshHeadingpubmed-meshheading:6099476-...lld:pubmed
pubmed-article:6099476pubmed:meshHeadingpubmed-meshheading:6099476-...lld:pubmed
pubmed-article:6099476pubmed:meshHeadingpubmed-meshheading:6099476-...lld:pubmed
pubmed-article:6099476pubmed:year1984lld:pubmed
pubmed-article:6099476pubmed:articleTitleOpioid binding sites in different levels of rat spinal cord.lld:pubmed
pubmed-article:6099476pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:6099476pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:6099476pubmed:publicationTypeIn Vitrolld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:6099476lld:pubmed